Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Azd7986
2. Ins-1007
3. Ins1007
4. N-(1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide
1. Azd7986
2. 1802148-05-5
3. Ins1007
4. (s)-n-((s)-1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide
5. Brensocatib [usan]
6. Azd 7986
7. Azd-7986
8. Ins-1007
9. 25cg88l0bb
10. Chembl3900409
11. (2s)-n-[(1s)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide
12. (s)-n-((s)-1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo-(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide
13. 1,4-oxazepine-2-carboxamide, N-((1s)-1-cyano-2-(4-(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)phenyl)ethyl)hexahydro-, (2s)-
14. Ins 1007
15. Brensocatib [inn]
16. Unii-25cg88l0bb
17. Brensocatib [who-dd]
18. Gtpl9412
19. Schembl16932317
20. Ex-a1866
21. Bdbm50195235
22. Pz1130
23. Who 11097
24. Ac-36222
25. As-84225
26. Bb177302
27. Hy-101056
28. Cs-0020766
29. J3.556.230c
30. A17095
31. D84088
32. A937370
33. (2s)-n-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
34. (s)-3-[4-(2-oxo-3-methyl-2,3-dihydrobenzoxazole-5-yl)phenyl]-2-[(hexahydro-1,4-oxazepine-2alpha-yl)carbonylamino]propanenitrile
| Molecular Weight | 420.5 g/mol |
|---|---|
| Molecular Formula | C23H24N4O4 |
| XLogP3 | 2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 5 |
| Exact Mass | 420.17975526 g/mol |
| Monoisotopic Mass | 420.17975526 g/mol |
| Topological Polar Surface Area | 104 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 699 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of non-cystic fibrosis bronchiectasis
Drugs in Development
Details:
INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Lead Product(s): Brensocatib
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: INS1007
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 24, 2025
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Won’t Hold Advisory Meeting to Discuss NDA for Brensocatib
Details : INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Product Name : INS1007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2025
Details:
INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Lead Product(s): Brensocatib
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: INS1007
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 10, 2024
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ASPEN Study Subgroup Shows Consistency in Brensocatib’s Efficacy in Bronchiectasis
Details : INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Product Name : INS1007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 10, 2024
Details:
Insmed intends to use the proceeds to fund continued research and development of INS1007 (brensocatib) as well as pre-commercial and, if approved, commercialization activities related to brensocatib.
Lead Product(s): Brensocatib
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: INS1007
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Goldman Sachs & Co
Deal Size: $650.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 30, 2024
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Goldman Sachs & Co
Deal Size : $650.0 million
Deal Type : Public Offering
Insmed Announces Pricing of $650 Million Public Offering of Common Stock
Details : Insmed intends to use the proceeds to fund continued research and development of INS1007 (brensocatib) as well as pre-commercial and, if approved, commercialization activities related to brensocatib.
Product Name : INS1007
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 30, 2024
Details:
The net proceeds will fund continued research and development of INS1007 (brensocatib), a small molecule, oral, reversible inhibitor of DPP1, for non-cystic fibrosis bronchiectasis.
Lead Product(s): Brensocatib
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: INS1007
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Goldman Sachs & Co
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 28, 2024
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Goldman Sachs & Co
Deal Size : $500.0 million
Deal Type : Public Offering
Insmed Announces Proposed $500 Million Public Offering of Common Stock
Details : The net proceeds will fund continued research and development of INS1007 (brensocatib), a small molecule, oral, reversible inhibitor of DPP1, for non-cystic fibrosis bronchiectasis.
Product Name : INS1007
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 28, 2024
Details:
INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Lead Product(s): Brensocatib
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: INS1007
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 28, 2024
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Insmed Announces Positive Results from ASPEN Study of Brensocatib in Bronchiectasis
Details : INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Product Name : INS1007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2024
Details:
INS1007 (brensocatib) is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases.
Lead Product(s): Brensocatib
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: INS1007
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 31, 2023
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : INS1007 (brensocatib) is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases.
Product Name : INS1007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2023
Details:
FDA has granted breakthrough therapy designation to brensocatib for treating patients with NCFBE, recognizing the strength of data from Company's Phase 2 WILLOW study and the potential for brensocatib to offer a novel, first-in-class treatment approach to bronchiectasis.
Lead Product(s): Brensocatib
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: INS1007
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 06, 2020
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FDA has granted breakthrough therapy designation to brensocatib for treating patients with NCFBE, recognizing the strength of data from Company's Phase 2 WILLOW study and the potential for brensocatib to offer a novel, first-in-class treatment approach t...
Product Name : INS1007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2020
Details:
New data from the Phase 2 WILLOW study of brensocatib (formerly known as INS1007) in non-cystic fibrosis bronchiectasis (NCFBE) will be presented during a virtual clinical trials session hosted by the American Thoracic Society (ATS).
Lead Product(s): Brensocatib
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: INS1007
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 20, 2020
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New data from the Phase 2 WILLOW study of brensocatib (formerly known as INS1007) in non-cystic fibrosis bronchiectasis (NCFBE) will be presented during a virtual clinical trials session hosted by the American Thoracic Society (ATS).
Product Name : INS1007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2020
Details:
Insmed will provide funding and clinical drug supply for the STOP-COVID19 trial led by the University of Dundee.
Lead Product(s): Brensocatib
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Other Small Molecule
Sponsor: Insmed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding April 24, 2020
Lead Product(s) : Brensocatib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Insmed
Deal Size : Undisclosed
Deal Type : Funding
Brensocatib to be Studied in Patients with Severe COVID-19 in Investigator-Initiated Trial
Details : Insmed will provide funding and clinical drug supply for the STOP-COVID19 trial led by the University of Dundee.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 24, 2020
Details:
Study Achieves Primary Endpoint with Statistically Significant Improvement in Time to First Exacerbation for Both Dosage Strengths of INS1007 Versus Placebo.
Lead Product(s): Brensocatib
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: INS1007
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 02, 2020
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study
Details : Study Achieves Primary Endpoint with Statistically Significant Improvement in Time to First Exacerbation for Both Dosage Strengths of INS1007 Versus Placebo.
Product Name : INS1007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
ABOUT THIS PAGE
52
PharmaCompass offers a list of Brensocatib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Brensocatib manufacturer or Brensocatib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Brensocatib manufacturer or Brensocatib supplier.
PharmaCompass also assists you with knowing the Brensocatib API Price utilized in the formulation of products. Brensocatib API Price is not always fixed or binding as the Brensocatib Price is obtained through a variety of data sources. The Brensocatib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Brensocatib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Brensocatib, including repackagers and relabelers. The FDA regulates Brensocatib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Brensocatib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Brensocatib supplier is an individual or a company that provides Brensocatib active pharmaceutical ingredient (API) or Brensocatib finished formulations upon request. The Brensocatib suppliers may include Brensocatib API manufacturers, exporters, distributors and traders.
Brensocatib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Brensocatib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Brensocatib GMP manufacturer or Brensocatib GMP API supplier for your needs.
A Brensocatib CoA (Certificate of Analysis) is a formal document that attests to Brensocatib's compliance with Brensocatib specifications and serves as a tool for batch-level quality control.
Brensocatib CoA mostly includes findings from lab analyses of a specific batch. For each Brensocatib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Brensocatib may be tested according to a variety of international standards, such as European Pharmacopoeia (Brensocatib EP), Brensocatib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Brensocatib USP).
